-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $14

Benzinga·05/12/2025 11:14:35
Listen to the news
D. Boral Capital analyst Jason Kolbert initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $14.